Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/23485
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLim, S.-
dc.contributor.authorGillis, D.-
dc.contributor.authorSmith, W.-
dc.contributor.authorHissaria, P.-
dc.contributor.authorGreville, H.-
dc.contributor.authorPeh, C.-
dc.date.issued2006-
dc.identifier.citationInternal Medicine Journal, 2006; 36(4):260-262-
dc.identifier.issn1444-0903-
dc.identifier.issn1445-5994-
dc.identifier.urihttp://hdl.handle.net/2440/23485-
dc.description.abstractRituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20+ B-cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab and review current reports on the use of rituximab in SLE.-
dc.description.statementofresponsibilityS.W. Lim, D. Gillis, W. Smith, P. Hissaria, H. Greville and C.A. Peh-
dc.language.isoen-
dc.publisherBlackwell Publishing Asia-
dc.source.urihttp://www3.interscience.wiley.com/journal/118576212/abstract-
dc.subjectrituximab-
dc.subjectsystemic lupus erythematosus-
dc.subjectpneumonitis-
dc.subjectB-cell depletion-
dc.subjectsystemic autoimmune disease-
dc.titleRituximab use in systemic lupus erythematosus pneumonitis and a review of current reports-
dc.typeJournal article-
dc.identifier.doi10.1111/j.1445-5994.2006.01055.x-
pubs.publication-statusPublished-
dc.identifier.orcidSmith, W. [0000-0001-9640-1172] [0000-0002-4610-998X]-
dc.identifier.orcidPeh, C. [0000-0002-9712-0396]-
Appears in Collections:Aurora harvest 2
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.